Review finds psychedelic therapy research uses scattered, inconsistent ways of measuring results

The question

How do researchers and clinicians currently measure what happens in psychedelic-assisted therapy, from screening through to follow-up, and where are the gaps?

What they did

The authors carried out a scoping review, a structured survey of what has already been published, following the PRISMA-ScR reporting guidelines. They analyzed 59 peer-reviewed publications from 2008 to 2026, including contemporary psychedelic-assisted therapy literature and the original sources for the questionnaires commonly used in the field. Findings were sorted into four areas: tools for measuring the subjective drug experience, treatment models and therapist skill frameworks, clinical and existential outcome measures, and safety, ethics and implementation.

What they found

The review found real progress in some areas: validated questionnaires for measuring mystical and difficult experiences now exist, including versions adapted for different cultures, and early work has begun to define the core skills a practitioner needs. Controlled studies have reported preliminary findings for depression, anxiety, post-traumatic stress disorder and existential distress, but the authors caution that trials have limited demographic diversity, small samples and difficulty keeping participants unaware of whether they received the drug. Key gaps included measurement domains rarely being combined into a single protocol, undervalidated measures for post-session integration and existential outcomes, and a lack of standardization in safety monitoring and implementation.

The fine print

A scoping review describes the literature; it does not test whether a treatment works or pool results statistically. The included 59 publications were selected by the authors, and the abstract does not describe how consistently they were screened or how many people took part in the underlying studies. The limitations the review flags in the primary trials, such as small samples and blinding problems, also limit any conclusions drawn from them. This summary is based on the abstract only.

What it means

The field currently measures psychedelic-assisted therapy in many different ways, which makes trial results hard to compare, and the authors argue that more standardized, joined-up assessment is needed before firm conclusions can be drawn.

Evidence grade: Low. A scoping review that maps and describes published methods rather than pooling results from controlled trials, so it cannot measure how well treatment works.

This summary is based on the study’s published abstract.